Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Sonoma Pharmaceuticals (SNOA) Cost of Revenue (2016 - 2025)

Sonoma Pharmaceuticals has reported Cost of Revenue over the past 16 years, most recently at $2.7 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 17.65% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $11.0 million, up 22.53%, while the annual FY2025 figure was $8.8 million, 10.43% up from the prior year.
  • Cost of Revenue for Q4 2025 was $2.7 million at Sonoma Pharmaceuticals, down from $3.5 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $3.5 million in Q3 2025 and troughed at $1.7 million in Q4 2023.
  • A 5-year average of $2.2 million and a median of $2.2 million in 2023 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: crashed 42.23% in 2021 and later soared 57.08% in 2025.
  • Year by year, Cost of Revenue stood at $1.7 million in 2021, then rose by 24.37% to $2.1 million in 2022, then fell by 20.59% to $1.7 million in 2023, then surged by 36.71% to $2.3 million in 2024, then increased by 17.65% to $2.7 million in 2025.
  • Business Quant data shows Cost of Revenue for SNOA at $2.7 million in Q4 2025, $3.5 million in Q3 2025, and $2.6 million in Q2 2025.